南非HIV感染女性中左炔诺孕酮宫内系统与铜宫内节育器的安全性和持续使用比较:一项随机对照试验
该双盲随机对照非劣效性试验在南非开普敦比较了HIV感染女性使用左炔诺孕酮宫内系统(LNG-IUS)与铜宫内节育器(C-IUD)的生殖道HIV病毒载量、血浆病毒载量及避孕续用率。结果显示两组生殖道病毒载量无显著差异,LNG-IUS组续用率更高且血红蛋白改善更明显,提示LNG-IUS对HIV疾病安全且可接受。
要点
- LNG-IUS与C-IUD在6和24个月时生殖道HIV病毒载量无显著差异。
- LNG-IUS组宫内节育器续用率更高,C-IUD组脱落和主动停用率显著更高。
- LNG-IUS组血红蛋白平均变化显著高于C-IUD组,且严重不良事件无组间趋势。
核心结论
- 在HIV感染女性中,LNG-IUS不增加生殖道或血浆HIV病毒载量,避孕失败和盆腔炎性疾病发生率低。
- LNG-IUS使用者更可能继续使用宫内节育器,且血红蛋白水平随时间更高,对HIV疾病安全且可接受。
研究设计与样本
- 双盲、随机对照非劣效性试验,在南非开普敦开展。
- 纳入18-40岁HIV感染女性,随机分配至LNG-IUS或C-IUD,按抗逆转录病毒治疗(ART)使用、年龄和近期注射孕激素暴露分层。
主要发现
- 可检测生殖道病毒载量比例在6个月(调整比值比[AOR] 0.78,95% CI 0.44-1.38,p=0.39)和24个月(AOR 1.03,95% CI 0.68-1.57,p=0.88)无显著差异。
- ART使用者中可检测血浆病毒载量比例在6个月(AOR 0.83,95% CI 0.37-1.86,p=0.65)和24个月(AOR 0.94,95% CI 0.49-1.81,p=0.85)无显著差异;非ART组6个月平均血浆病毒载量差异无统计学意义(-0.10 log10 copies/mL,95% CI -0.29 to 0.10,p=0.50)。
- 宫内节育器总续用率为78%;C-IUD组脱落率(8% vs 1%,p=0.02)和主动停用率(调整风险比8.75,95% CI 3.08-24.8,p<0.001)显著更高。
- LNG-IUS组血红蛋白平均变化在6个月(0.57 g/dL,95% CI 0.24-0.90;p<0.001)和24个月(0.71 g/dL,95% CI 0.47-0.95;p<0.001)显著更高。
- 严重不良事件39例,其中7例认为与宫内节育器使用直接相关(3例盆腔炎性疾病,4例带器妊娠),无组间趋势。
关键数值与推荐
- 宫内节育器续用率总体78%,C-IUD组脱落率8% vs LNG-IUS组1%(p=0.02)。
- C-IUD组主动停用调整风险比8.75(95% CI 3.08-24.8,p<0.001)。
- LNG-IUS组血红蛋白平均变化6个月0.57 g/dL(95% CI 0.24-0.90),24个月0.71 g/dL(95% CI 0.47-0.95)。
临床怎么用
- 对于HIV感染女性,LNG-IUS不增加HIV病毒载量,可安全使用。
- LNG-IUS具有更高的续用率和血红蛋白改善,可作为优先推荐的避孕选择。
局限性
- 非ART组样本量未达到目标,因ART治疗指南变更。
- 24个月结局数据被截断,研究结束时17名女性尚未到24个月访视。
- 研究期间病毒载量检测方法变更可能导致病毒载量值差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women living with HIV (WLHIV) have lower rates of contraceptive use than noninfected peers, yet concerns regarding contraceptive efficacy and interaction with antiretroviral therapy (ART) complicate counseling. Hormonal contraceptives may increase genital tract HIV viral load (gVL) and sexual transmission risk to male partners. We compared gVL, plasma VL (pVL), and intrauterine contraceptive (IUC) continuation between the levonorgestrel intrauterine system (LNG-IUS) and copper intrauterine device (C-IUD) in Cape Town, South Africa. METHODS AND FINDINGS: In this double-masked, randomized controlled noninferiority trial, eligible WLHIV were ages 18-40, not pregnant or desiring pregnancy within 30 months, screened and treated (as indicated) for reproductive tract infections (RTIs) within 1 month of enrollment, and virologically suppressed using ART or above treatment threshold at enrollment (non-ART). Between October 2013, and December 2016, we randomized consenting women within ART groups, using 1:1 permuted block randomization stratified by ART use, age (18-23, 24-31, 32-40), and recent injectable progestin contraceptive (IPC) exposure, and provided the allocated IUC. At all visits, participants provided specimens for gVL (primary outcome), pVL, RTI, and pregnancy testing. We assessed gVL and pVL across 6 and 24 months controlling for enrollment measures, ART group, age, and RTI using generalized estimating equation and generalized linear models (non-ART group pVL and hemoglobin) in as-treated analyses. We measured IUC discontinuation rates with Kaplan-Meier estimates and Cox proportional hazards models. We enrolled 71 non-ART (36 LNG-IUS, 31 C-IUD; 2 declined and 2 were ineligible) and 134 ART-using (65 LNG-IUS, 67 C-IUD; 1 declined and 1 could not complete IUC insertion) women. Participant median age was 31 years, and 95% had 1 or more prior pregnancies. Proportions of women with detectable gVL were not significantly different comparing LNG-IUS to C-IUD across 6 (adjusted odds ratio [AOR]: 0.78, 95% confidence interval [CI] 0.44-1.38, p = 0.39) and 24 months (AOR: 1.03, 95% CI: 0.68-1.57, p = 0.88). Among ART users, proportions with detectable pVL were not significantly different at 6 (AOR = 0.83, 95% CI 0.37-1.86, p = 0.65) and 24 months (AOR = 0.94, 95% CI 0.49-1.81, p = 0.85), whereas among non-ART women, mean pVL was not significantly different at 6 months (-0.10 log10 copies/mL, 95% CI -0.29 to 0.10, p = 0.50) between LNG-IUS and C-IUD users. IUC continuation was 78% overall; C-IUD users experienced significantly higher expulsion (8% versus 1%, p = 0.02) and elective discontinuation (adjusted hazard ratio: 8.75, 95% CI 3.08-24.8, p < 0.001) rates. Sensitivity analysis adjusted for differential IUC discontinuation found similar gVL results. There were 39 serious adverse events (SAEs); SAEs believed to be directly related to IUC use (n = 7) comprised 3 pelvic inflammatory disease (PID) cases and 4 pregnancies with IUC in place with no discernible trend by IUC arm. Mean hemoglobin change was significantly higher among LNG-IUS users across 6 (0.57 g/dL, 95% CI 0.24-0.90; p < 0.001) and 24 months (0.71 g/dL, 95% CI 0.47-0.95; p < 0.001). Limitations included not achieving non-ART group sample size following change in ART treatment guidelines and truncated 24 months' outcome data, as 17 women were not yet eligible for their 24-month visit at study closure. Also, a change in VL assay during the study may have caused some discrepancy in VL values because of different limits of detection. CONCLUSIONS: In this study, we found that the LNG-IUS did not increase gVL or pVL and had low levels of contraceptive failure and associated PID compared with the C-IUD among WLHIV. LNG-IUS users were significantly more likely to continue IUC use and had higher hemoglobin levels over time. The LNG-IUS appears to be a safe contraceptive with regard to HIV disease and may be a highly acceptable option for WLHIV. TRIAL REGISTRATION: ClinicalTrials.gov NCT01721798.
引用
- Todd CS, Jones HE, Langwenya N, et al. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial. PLoS Med. 2020. PMID: 32442189. doi:10.1371/journal.pmed.1003110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。